These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35500152)

  • 1. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
    Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
    J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma.
    Chen J; Jiang F; Hu L; Zhang F; Wang J; Huang K; Wang Y
    Biomed Res Int; 2020; 2020():2806042. PubMed ID: 32626737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
    BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells.
    Tan D; Li G; Zhang P; Peng C; He B
    Bioengineered; 2022 Jan; 13(1):1838-1857. PubMed ID: 35014944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA PCIF1 promotes aerobic glycolysis in A549/DDP cells by competitively binding miR-326 to regulate PKM expression.
    Zhong W; Wang C; Sun Y
    Mol Cell Probes; 2024 Oct; 77():101977. PubMed ID: 39074568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.
    Zhou H; Huang X; Shi W; Xu S; Chen J; Huang K; Wang Y
    Cell Cycle; 2022 Jul; 21(13):1391-1405. PubMed ID: 35298351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
    Wang W; Dong ML; Zhang W; Liu T
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
    Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
    Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silence of  lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
    Liu X; Huang Z; Qian W; Zhang Q; Sun J
    J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation.
    Chen Y; Wu S; Han Y; Shi H; Yuan J; Cui W
    BMC Cancer; 2024 Jul; 24(1):848. PubMed ID: 39020302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
    Shen JG; Xu SN; Yin LG
    Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
    Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
    Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.